DE69213067T2 - Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen - Google Patents

Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen

Info

Publication number
DE69213067T2
DE69213067T2 DE69213067T DE69213067T DE69213067T2 DE 69213067 T2 DE69213067 T2 DE 69213067T2 DE 69213067 T DE69213067 T DE 69213067T DE 69213067 T DE69213067 T DE 69213067T DE 69213067 T2 DE69213067 T2 DE 69213067T2
Authority
DE
Germany
Prior art keywords
group
dimethyl
phosphonate
aldehyde
oxoalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69213067T
Other languages
German (de)
English (en)
Other versions
DE69213067D1 (de
Inventor
Tomio Oda
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK, R Tech Ueno Ltd filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of DE69213067D1 publication Critical patent/DE69213067D1/de
Application granted granted Critical
Publication of DE69213067T2 publication Critical patent/DE69213067T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69213067T 1991-04-04 1992-04-03 Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen Expired - Fee Related DE69213067T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (2)

Publication Number Publication Date
DE69213067D1 DE69213067D1 (de) 1996-10-02
DE69213067T2 true DE69213067T2 (de) 1997-01-16

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69213067T Expired - Fee Related DE69213067T2 (de) 1991-04-04 1992-04-03 Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen

Country Status (11)

Country Link
US (1) US5229529A (enExample)
EP (1) EP0507625B1 (enExample)
JP (1) JPH089608B2 (enExample)
KR (1) KR970003125B1 (enExample)
AT (1) ATE141921T1 (enExample)
CA (1) CA2064481C (enExample)
DE (1) DE69213067T2 (enExample)
DK (1) DK0507625T3 (enExample)
ES (1) ES2093776T3 (enExample)
GR (1) GR3020903T3 (enExample)
TW (1) TW197439B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT643051E (pt) * 1992-09-30 2000-06-30 R Tech Ueno Ltd Processo de producao de cetonas alfa,beta-insaturadas
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
EP1633317A4 (en) 2003-05-16 2008-08-20 Intermune Inc Synthetic chemokine receptor ligands and methods of use therefor
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
EP1789074A4 (en) * 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
RU2448697C2 (ru) 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
EP2043704B2 (en) 2006-06-30 2017-04-19 Cook Medical Technologies LLC Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
ES2833157T3 (es) 2014-02-19 2021-06-14 Aviv Therapeutics Inc Amidas políciclicas de unión a aldehído deshidrogenasa 2 mitocondrial (aldh2) y su uso para el tratamiento del cáncer
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
WO2018017190A2 (en) 2016-06-01 2018-01-25 Baxalta Incorporated Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
MX2020008028A (es) 2018-01-31 2020-12-11 Galera Labs Llc Terapia de combinacion para cancer con complejo de anillo macrociclico de pentaaza y agente anticancer basado en platino.
AU2019249215B2 (en) 2018-04-06 2026-02-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096838A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020148612A1 (en) 2019-01-14 2020-07-23 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
BR112021019701A2 (pt) 2019-04-02 2021-12-14 Kenjockety Biotechnology Inc Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
CA3163805A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
JP7815595B2 (ja) 2020-01-29 2026-02-18 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 抗ｍｄｒ１抗体およびその使用
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
US20220033784A1 (en) 2020-07-14 2022-02-03 Pfizer Inc. Recombinant vaccinia virus
JP7747741B2 (ja) 2020-09-02 2025-10-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 抗ａｂｃｃ１抗体及びその使用
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
EP4247829A1 (en) 2020-11-20 2023-09-27 R.P. Scherer Technologies, LLC Glycoside dual-cleavage linkers for antibody-drug conjugates
US20250051471A1 (en) 2021-12-13 2025-02-13 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-Abcb1 Antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (enExample) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
EP0219580B1 (en) * 1985-09-18 1989-11-29 The Upjohn Company Stereo-selective reduction
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
AU2130288A (en) * 1987-09-04 1989-03-31 Upjohn Company, The Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
DK0507625T3 (da) 1996-09-16
KR970003125B1 (ko) 1997-03-14
ATE141921T1 (de) 1996-09-15
GR3020903T3 (en) 1996-11-30
TW197439B (enExample) 1993-01-01
US5229529A (en) 1993-07-20
EP0507625A1 (en) 1992-10-07
KR920019771A (ko) 1992-11-20
ES2093776T3 (es) 1997-01-01
DE69213067D1 (de) 1996-10-02
JPH089608B2 (ja) 1996-01-31
CA2064481C (en) 1996-12-24
CA2064481A1 (en) 1992-10-05
EP0507625B1 (en) 1996-08-28
JPH0592965A (ja) 1993-04-16

Similar Documents

Publication Publication Date Title
DE69213067T2 (de) Methode zur Herstellung von alpha, beta ungesättigten Ketolactonen
DE2900352C2 (de) Carbacyclinderivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2330333C2 (de) 9-Desoxy-prosta-5,9(10),13-triensäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Zubereitungen
EP0062902B1 (de) 2,3,4-Trinor-m-inter-phenylen-prostaglandin-Derivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende pharmazeutische Präparate
EP0001089B1 (de) Verfahren zur Herstellung von halogenvinylsubstituierten Tetrahydrofuran-2-onen, bestimmte halogenvinylsubstituierte Tetrahydrofuran-2-one
DE2611788C2 (de) Fluorprostaglandine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
DE69308965T2 (de) Verfahren zum Herstellen einer gesättigten monocyclischen Kohlenwasserstoffverbindung und ein Zwischenprodukt für dieses
DE2610503C2 (de) Optisch aktive 13,14-Dehydro-11- desoxy-prostaglandine, Verfahren zu ihrer Herstellung und sie enthaltendes pharmazeutisches Mittel
DE2463208C2 (de) Verfahren zur Herstellung von optisch aktiven bicyclischen Lactondiolen und deren racemischen Gemischen
DE69125675T2 (de) In situ-Herstellung von Diisopinocampheylchloroboran
EP0236884B1 (de) Verfahren zur Herstellung von Phenoxyalkanoltriazolverbindungen und Zwischenprodukte hierfür
DE69327717T2 (de) Verfahren zur herstellung von alpha, beta-ungesättigten ketonen
DE3338832C2 (enExample)
DE3871862T2 (de) Thiophenverbindungen und deren herstellung.
DE68911295T2 (de) Verfahren zur herstellung von 2-oxo-3-aromatischen karbonsäure-derivaten.
DE2655004C3 (de) Verfahren zur Herstellung von bicyclischen Laktonen
DE69115389T2 (de) Cyclohexenol Derivate
DE2847049A1 (de) 13,14-didehydro-prostaglandine, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches oder veterinaermedizinisches mittel
CH628639A5 (en) Process for the preparation of furanose derivatives
DE2707404C3 (de) Verfahren zur Herstellung von 5,6-Dehydropenicillinen
DE3715704A1 (de) Ss-fluoracyl-ss-halogenvinylalkylether
DE19735574A1 (de) Neue [C1(Carboxa)-C6]-Fragmente, Verfahren zu ihrer Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE2654668A1 (de) Verfahren zur herstellung von verbindungen des prostaglandintyps und nach diesem verfahren erhaltene produkte
DE3121177C2 (enExample)
CH617424A5 (enExample)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee